Kunming Pharmaceutical Group
Corporate brand
UnclaimedKunming Pharmaceutical Group is a Chinese pharmaceutical company with a portfolio spanning traditional Chinese medicines, plant-based medicines, prescription products, and health products.
Last updated October 13, 2026
Overview
Kunming Pharmaceutical Group, also known as KPC, is a pharmaceutical company established in 1951 and listed on the Shanghai Stock Exchange in 2000 under stock code 600422. The company presents itself as an experienced drug maker with a history of pharmaceutical research and development. Its stated capabilities include the development of natural plant medicines, distinctive traditional Chinese medicines, and ethnic medicines. The company reports having developed more than 40 such products and holding 68 effective invention patents. Its official product catalogue is organized into series that include artemisia, notoginseng, gastrodia, distinctive plant medicines, premium Chinese medicines, global classic prescription products, health products, and other medicines. This breadth places traditional Chinese medicine and plant-derived products at the heart of its public-facing identity, alongside prescription and broader health offerings. The company’s media materials refer to artemisinin-related products, Xuesaitong, and Tianxuanqing, though the cited pages do not provide a complete account of the products’ indications or market performance. Kunming Pharmaceutical Group’s stated strategic direction is to carry forward premium Chinese medicines, build around the notoginseng industry chain, serve the health needs of older adults, and expand into chronic-disease management. Its own description frames this as an ambition to become a leading company in the “silver health” sector. The company also maintains an international section and features media coverage of efforts to take its artemisinin-related medicines to international markets; the available evidence does not establish the scale or specific countries of its international business. The official website identifies a network of controlled member companies and affiliated links involved in pharmaceutical manufacturing, commerce, and related activities. These include Kunming Chinese Medicine Factory, Kunming Pharmaceutical Group Xuesaitong Pharmaceutical, Xishuangbanna Banna Pharmaceutical, Kunming Pharmaceutical Group Pharmaceutical Commerce, Kunming Baker Norton Pharmaceutical, and other named entities. The supplied evidence does not establish the current ultimate parent or ownership structure, so none is asserted here.
History
Kunming Pharmaceutical Group states that it was established in 1951. The company’s official introduction describes more than seven decades of pharmaceutical research and development experience. It says it has developed more than 40 products across natural plant medicines, distinctive traditional Chinese medicines, and distinctive ethnic medicines, and reports 68 effective invention patents. These details establish a long-standing manufacturing and R&D identity, but the supplied material does not specify the company’s original founders or provide a year-by-year account of its early development. A dated corporate milestone given by the company is its listing on the Shanghai Stock Exchange in 2000. Its official homepage identifies the company with stock code 600422. Beyond that listing, the available evidence does not provide a detailed chronology of shareholding changes, acquisitions, or management transitions, so those events are not added here. The current official product structure groups offerings into artemisia, notoginseng, gastrodia, distinctive plant medicines, premium Chinese medicines, global classic prescription products, health products, and other products. The official media archive points to particular product and company-history themes: artemisinin-related medicines and their international development, the thirtieth anniversaries of Xuesaitong and Tianxuanqing launches, and the company’s seventieth-anniversary promotional film. The archive titles identify these as subjects of company communications, but do not provide enough detail to reconstruct the underlying product-launch histories or verify specific development dates. The company’s stated strategic focus is to carry forward premium Chinese medicines, make the notoginseng industry chain central to its business, serve older-adult health needs, and develop chronic-disease management. It describes its intended role as becoming a leader in the silver-health industry. The official site also presents international business and international certification as areas of activity, while its media page refers to artemisinin-series medicines moving toward international markets. The evidence does not specify the countries involved or quantify international operations. The official site lists controlled member companies and related links spanning medicine manufacturing and pharmaceutical commerce. Among those named are Kunming Chinese Medicine Factory, Kunming Pharmaceutical Group Xuesaitong Pharmaceutical, Xishuangbanna Banna Pharmaceutical, and Kunming Pharmaceutical Group Pharmaceutical Commerce. Because the supplied pages do not identify an ultimate parent or a current ownership breakdown, the group’s present ownership is left unspecified.
- 2000
Listed on the Shanghai Stock Exchange
- 1951
Kunming Pharmaceutical Group established
Products and positioning
A pharmaceutical company emphasizing premium traditional Chinese medicines, plant-derived medicines, the notoginseng industry chain, and health needs associated with aging and chronic-disease management.
Artemisia-series products
A product category listed by the company; its media page also features material about artemisinin-series medicines.
Notoginseng-series products
A product category emphasized in the company’s catalogue and strategic description.
Gastrodia-series products
A product category listed in the official product catalogue.
Xuesaitong
A named offering featured in company media, including a video marking the thirtieth anniversary of its launch.
Tianxuanqing
A named offering featured in company media, including a video marking the thirtieth anniversary of its launch.
Controversies
Brand decisions
- Strategic emphasis on notoginseng, older-adult health, and chronic-disease managementOther
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/昆药集团 · Editorial policy · How profiles are compiled